Structure-Based Discovery of a Novel Angiotensin-Converting Enzyme 2 Inhibitor

No abstract is available for this paper.

• Publication year

  2004

• Venue

  HYPERTENSION

• Publication date

  2004-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1161/01.HYP.0000146120.29648.36PMID 15492138
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Copyright

  2005cited by this paper
• Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

  2004cited by this paper
• Calculation of ligand‐nucleic acid binding free energies with the generalized‐born model in DOCK

  2004cited by this paper
• A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2*

  2004cited by this paper
• ACE2 X-Ray Structures Reveal a Large Hinge-bending Motion Important for Inhibitor Binding and Catalysis

  2004cited by this paper
• ACE2 gene expression is up-regulated in the human failing heart

  2004cited by this paper
• ACE2, a new regulator of the renin–angiotensin system

  2004cited by this paper
• Expression cloning of functional receptor used by SARS coronavirus

  2004cited by this paper
• Cloning and characterization of a secreted form of angiotensin-converting enzyme 2.

  2004cited by this paper
• Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors

  2004cited by this paper
• Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence.

  2003cited by this paper
• A story of two ACEs

  2003cited by this paper
• Angiotensin-I-converting enzyme and its relatives

  2003cited by this paper
• Hypothesis: ACE2 modulates blood pressure in the mammalian organism.

  2003cited by this paper
• Novel Peptide Inhibitors of Angiotensin-converting Enzyme 2*

  2003cited by this paper
• Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

  2003cited by this paper
• A model of the ACE2 structure and function as a SARS-CoV receptor

  2003cited by this paper
• The SARS-CoV S glycoprotein: expression and functional characterization

  2003cited by this paper
• Characterization of Renal Angiotensin-Converting Enzyme 2 in Diabetic Nephropathy

  2003cited by this paper
• Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins.

  2003cited by this paper
• Increased Angiotensin-(1-7)–Forming Activity in Failing Human Heart Ventricles: Evidence for Upregulation of the Angiotensin-Converting Enzyme Homologue ACE2

  2003cited by this paper
• The role of ACE2 in cardiovascular physiology.

  2003cited by this paper
• The angiotensin-converting enzyme gene family: genomics and pharmacology.

  2002cited by this paper
• Developmental Therapeutics Program at the NCI: molecular target and drug discovery process

  2002cited by this paper
• Just the beginning: novel functions for angiotensin-converting enzymes.

  2002cited by this paper
• Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors.

  2002cited by this paper
• Molecule of the month. ACE2: an attractive new target for cardiovascular drug discovery.

  2001cited by this paper

• ACE2, a therapeutic target of COVID-19, needs to be treated with caution

  2025cites this paper
• Advancements in the development of antivirals against SARS-Coronavirus

  2025cites this paper
• MicroRNAs modulate SARS‐CoV‐2 infection of primary human hepatocytes by regulating the entry factors ACE2 and TMPRSS2

  2024cites this paper
• Ringing medicinal chemistry: The importance of 3-membered rings in drug discovery.

  2024cites this paper
• Dietary fish intake increased the concentration of soluble ACE2 in rats: can fish consumption reduce the risk of COVID-19 infection through interception of SARS-CoV-2 by soluble ACE2?

  2023cites this paper
• Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2

  2023cites this paper
• Allosteric communication between ACE2 active site and binding interface with SARS-CoV-2.

  2023cites this paper
• Crosstalk between SARS-CoV-2 Infection and Type II Diabetes.

  2022cites this paper
• Effect of an Inhibitor on the ACE2-Receptor-Binding Domain of SARS-CoV-2

  2022cites this paper
• Susceptibility to Metabolic Diseases in COVID-19: To be or Not to be an Issue

  2022cites this paper
• Inhibition of ACE2‐Spike Interaction by an ACE2 Binder Suppresses SARS‐CoV‐2 Entry

  2022cites this paper
• Structural biology of SARS-CoV-2: open the door for novel therapies

  2022cites this paper
• Binding Analysis Using Accelerated Molecular Dynamics Simulations and Future Perspectives

  2022cites this paper
• Intricate relationship between SARS-CoV-2–induced shedding and cytokine storm generation: A signaling inflammatory pathway augmenting COVID-19

  2022cites this paper
• Six Decades of History of Hypertension Research at the University of Toledo: Highlighting Pioneering Contributions in Biochemistry, Genetics, and Host-Microbiota Interactions

  2022cites this paper
• Current therapeutic strategies and possible effective drug delivery strategies against COVID-19.

  2022cites this paper
• Engineering ACE2 decoy receptors to combat viral escapability

  2022cites this paper
• Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.

  2022cites this paper
• Bhimamycin J, a Rare Benzo[f]isoindole‐dione Alkaloid from the Marine‐Derived Actinomycete Streptomyces sp. MS180069

  2021cites this paper
• Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants

  2021cites this paper
• Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2

  2021cites this paper
• Coronavirus Disease 2019: An Overview of the Complications and Management

  2021cites this paper
• Inhibition of multiple SARS-CoV-2 proteins by an antiviral biomolecule, seselin from Aegle marmelos deciphered using molecular docking analysis

  2021cites this paper
• The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2

  2021cites this paper
• Dietary supplements, vitamins and minerals as potential interventions against viruses: Perspectives for COVID-19.

  2021cites this paper
• Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury

  2021cites this paper
• Enzyme inhibition as a potential therapeutic strategy to treat COVID-19 infection

  2021cites this paper
• Determining available strategies for prevention and therapy: Exploring COVID-19 from the perspective of ACE2 (Review)

  2021cites this paper
• Ensemble-based screening of natural products and FDA-approved drugs identified potent inhibitors of SARS-CoV-2 that work with two distinct mechanisms

  2021cites this paper
• Brief review on repurposed drugs and vaccines for possible treatment of COVID-19

  2021cites this paper
• Cyclic 68Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2

  2021cites this paper
• Identification and Development of Therapeutics for COVID-19

  2021cites this paper
• An Overview of Spike Surface Glycoprotein in Severe Acute Respiratory Syndrome–Coronavirus

  2021cites this paper
• Human coronaviruses and therapeutic drug discovery

  2021cites this paper
• Common dandelion (Taraxacum officinale) efficiently blocks the interaction between ACE2 cell surface receptor and SARS-CoV-2 spike protein D614, mutants D614G, N501Y, K417N and E484K in vitro

  2021cites this paper
• Discovery and in-vitro evaluation of potent SARS-CoV-2 entry inhibitors

  2021cites this paper
• Targeting the viral‐entry facilitators of SARS‐CoV‐2 as a therapeutic strategy in COVID‐19

  2021cites this paper
• Human respiratory viral infections: Current status and future prospects of nanotechnology-based approaches for prophylaxis and treatment

  2021cites this paper
• Quinoline and Quinazoline Alkaloids against COVID-19: An In Silico Multitarget Approach

  2021cites this paper
• Peptide‐Based Inhibitors for SARS‐CoV‐2 and SARS‐CoV

  2021cites this paper
• Structural Basis for the Understanding of Entry Inhibitors Against SARS Viruses.

  2021cites this paper
• Mechanism of Ligand Recognition by Human ACE2 Receptor

  2021cites this paper
• “Molecular Masks” for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry

  2021cites this paper
• In Silico Comparison of Separate or Combinatorial Effects of Potential Inhibitors of the SARS-CoV-2 Binding Site of ACE2

  2021cites this paper
• Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?

  2021cites this paper
• Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2)

  2021cites this paper
• SARS-CoV-2 Spike Protein Extrapolation for COVID Diagnosis and Vaccine Development

  2021cites this paper
• Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19

  2021cites this paper
• Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses.

  2021cites this paper
• The interaction of the severe acute respiratory syndrome coronavirus 2 spike protein with drug-inhibited angiotensin converting enzyme 2 studied by molecular dynamics simulation

  2021influential citation
• Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2

  2021cites this paper
• Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2

  2021cites this paper
• Potential Drug Strategies to Target Coronaviruses.

  2021cites this paper
• Lipophilic Efficiency as an Important Metric in the Design of SARS coronavirus 3C-like proteinase (3CL-pro) Inhibitors: Guidepost towards Lead Selection and Optimization in the Treatment of COVID-19

  2021cites this paper
• Potential COVID‐19 therapeutic approaches targeting angiotensin‐converting enzyme 2; An updated review

  2021cites this paper
• Interactions of renin-angiotensin system and COVID-19: the importance of daily rhythms in ACE2, ADAM17 and TMPRSS2 expression.

  2021cites this paper
• Identification and Development of Therapeutics for COVID-19

  2021cites this paper
• Potential inhibitors and plant based technology: An alternative approach to treat corona virus

  2021influential citation
• ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review

  2021cites this paper
• In Vitro Effect of Taraxacum officinale Leaf Aqueous Extract on the Interaction between ACE2 Cell Surface Receptor and SARS-CoV-2 Spike Protein D614 and Four Mutants

  2021cites this paper
• Molecular modeling of the interaction of ligands with ACE2–SARS-CoV-2 spike protein complex

  2021cites this paper
• Identification of antiviral antihistamines for COVID-19 repurposing

  2020cites this paper
• A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor

  2020cites this paper
• Role of Long-range Allosteric Communication in Determining the Stability and Disassembly of SARS-COV-2 in Complex with ACE2

  2020cites this paper
• Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges

  2020influential citation
• Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules

  2020cites this paper
• Возможность и перспективы применения блокаторов рецептора ангиотензина 2-го типа у пациентов с COVID-19

  2020cites this paper
• Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication

  2020cites this paper
• Bradykinin System: A Therapeutic Goal for COVID-19

  2020cites this paper
• Cyclic gallium-68 labeled peptides for specific detection of human angiotensin-converting enzyme 2

  2020cites this paper
• Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics

  2020cites this paper
• The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities

  2020cites this paper
• Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19

  2020cites this paper
• Screening Virtual ACE2 Enzyme Inhibitory Activity of Compounds for COVID-19 Treatment Based on Molecular Docking

  2020cites this paper
• Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients

  2020cites this paper
• Recent discovery and development of inhibitors targeting coronaviruses

  2020cites this paper
• Structure analysis of the receptor binding of 2019-nCoV

  2020cites this paper
• Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics

  2020cites this paper
• The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease

  2020cites this paper
• Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV

  2020cites this paper
• Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.

  2020cites this paper
• The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

  2020cites this paper
• Perspectives for repurposing drugs for the coronavirus disease 2019

  2020cites this paper
• The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses

  2020cites this paper
• Yin-Yang Balance of ACE/ACE2 Pathways: The Rational for ACE2 Pathway Inhibitor Administration in SARS-CoV-2 Patients

  2020cites this paper
• Candidate drugs against SARS-CoV-2 and COVID-19

  2020cites this paper
• Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management

  2020cites this paper
• Expression Pattern of the SARS-CoV-2 Receptor ACE2 and TMPRSS2 in the Respiratory Tract

  2020cites this paper
• ACE Inhibitors and AT1R Blockers for COVID-2019: Friends or Foes ?

  2020cites this paper
• Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases

  2020cites this paper
• Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug

  2020cites this paper
• Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities

  2020cites this paper
• Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community

  2020cites this paper
• SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients

  2020cites this paper
• SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries

  2020cites this paper
• The role of angiotensin-converting enzyme 2 in the pathogenesis of COVID-19: the villain or the hero?

  2020cites this paper
• Angiotensin‐converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection

  2020cites this paper
• Current Findings Regarding Natural Components With Potential Anti-2019-nCoV Activity

  2020cites this paper
• Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review

  2020cites this paper
• ACE2, the Receptor that Enables Infection by SARS‐CoV‐2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators

  2020cites this paper